The Cigna Group reported strong second quarter 2026 results, with total revenues increasing 7% to $71.7 billion. Shareholders' net income reached $1.7 billion, or $6.29 per share, whilst adjusted income from operations was $2.1 billion, or $7.78 per share. Based on these results, the company raised its full-year 2026 outlook for adjusted income from operations to at least $30.45 per share, an increase of $0.10 from its previous projection. The healthcare company's performance was driven by growth across its diversified portfolio, particularly in Cigna Healthcare. Total customer relationships stood at 182.8 million at quarter end. Chief Executive Officer Brian Evanko attributed the strong performance to the company's strategy of using technology, data and artificial intelligence to deliver more personalised experiences whilst improving access and lowering costs.

Cigna Group Foundation awards $250,000 to Hartford Hospital's Food4Health program. June 18, 2026 Hartford Hospital was awarded a generous $250,000 grant through The Cigna Group Health Equity Impact Fund by The Cigna Group Foundation, the philanthropic arm of The Cigna Group, to expand access to its innovative Food4Health program and reduce health disparities among underserved populations in the Hartford region. Food4Health is a prescription-based program for low-income patients experiencing food insecurity and at risk of diet-related illnesses. Participants visit the hospital's Food4Health Clinic weekly to shop for nutritious foods and recipes at no cost and receive medical guidance on healthy eating and food preparation. The clinic has had over 10,000 patient visits and distributed more than 3 million pounds of food since 2022. The Cigna Group Foundation's investment will increase access and remove barriers to Food4Health participation by providing transportation assistance, shopping carts and food delivery services to underserved patients. The program will also pilot two part-time community health workers charged with guiding Food4Health patients through transportation support, healthy lifestyle changes and access to healthcare. "Programs like Food4Health only work if people can access them," said Ellie Polack, president, The Cigna Group Foundation. "For many patients, transportation is a major barrier. As a company headquartered here in Connecticut, we're proud to support programs like this in our own community, helping more people get the food and guidance they need to improve their health." "Food4Health is changing what care can look like - bringing nutrition, clinical support and guidance together in a way that truly meets patients where they are," said Lynn B. Rossini, interim chief philanthropy officer, Hartford HealthCare, and vice president of Philanthropy at Hartford Hospital. "We're grateful to The Cigna Group Foundation for this support, which allows us to reach more patients and build the kind of lasting change that our community needs."

Cigna (CI) has a 2026 growth story that looks bigger than medical costs. Why Cigna's thesis now runs through Evernorth as much as insurance. The usual shorthand on The Cigna Group is to treat it as an insurer whose stock lives and dies on medical-cost trends. That misses where most of the scale sits. In the first quarter of 2026, Cigna generated $68.5 billion of total revenue, and Evernorth Health Services alone produced $58.4 billion of adjusted revenue, compared with $11.5 billion for Cigna Healthcare adjusted revenue (The Cigna Group Q1 2026 release). Evernorth combines pharmacy benefit services with specialty and care services, giving Cigna an earnings base tied to drug mix, specialty distribution, and care delivery rather than only to insurance underwriting. That pattern was also visible in full-year 2025. Total revenue rose 11% to $274.9 billion, driven primarily by Evernorth, while adjusted income from operations increased 4% to $8.0 billion, or $29.84 per share (The Cigna Group FY2025 release). The long-run case increasingly depends on whether Evernorth can keep compounding through specialty volume and biosimilar adoption. How specialty mix and pricing discipline are shaping 2026 earnings. The first quarter shows why this is more than a simple membership story. Evernorth's adjusted revenue increased 9% year over year to $58.4 billion, while pre-tax adjusted income from operations increased 2% to $1.47 billion (The Cigna Group Q1 2026 release). The internal mix shift is the real story. Pharmacy Benefit Services revenue rose 11% to $33.0 billion, but pre-tax income fell 28% to $394 million because of expected lower contributions from large client relationships. Specialty and Care Services offset that: adjusted revenue rose 6% to $25.4 billion and pre-tax income climbed 20% to $1.07 billion, helped by specialty growth and higher generic and biosimilar adoption (The Cigna Group Q1 2026 release). Cigna Healthcare also gave the company a cleaner setup than the market often assumes. First-quarter 2026 adjusted revenue declined 21% to $11.5 billion, mainly because the Medicare businesses were sold to HCSC in March 2025, but adjusted income from operations before tax still increased 18% to $1.51 billion. The Cigna Healthcare medical care ratio improved to 79.8% from 82.2% a year earlier, and the company said underlying revenue excluding the HCSC transaction rose 8% because pricing increased to cover expected medical costs (The Cigna Group Q1 2026 release). That is a useful signal: Cigna is showing it can shrink lower-priority exposure, reprice commercial risk, and still improve profitability. Why the balance sheet and buybacks still matter to the CI story. CI is also not just a medical-cost trade because management still has capital allocation flexibility. Cigna ended March 31, 2026 with $7.0 billion of cash and cash equivalents, according to the 10-Q, and its debt-to-capitalization ratio improved to 42.3% from 43.0% at year-end 2025 (Cigna Q1 2026 10-Q). Capital return is already part of the earnings model. In full-year 2025, Cigna repurchased 11.9 million shares for about $3.6 billion, and it raised the quarterly dividend to $1.56 per share in February 2026 from $1.51 in 2025 (The Cigna Group FY2025 release). The first-quarter 2026 outlook also explicitly included the effect of expected future share repurchases, meaning buybacks are embedded in how management frames per-share earnings power (The Cigna Group Q1 2026 release). That matters after the Medicare divestiture. Cigna has already shown willingness to reshape the portfolio instead of defending every line of business. A company with a large services platform, steadier commercial pricing, and ongoing buybacks can still compound even if it no longer looks like a traditional membership-growth story. What investors should watch next in the Cigna Healthcare and Evernorth segments. The next watchpoint is whether Evernorth keeps shifting toward the parts of the business that carry better strategic value. Specialty and Care Services delivered stronger income growth than Pharmacy Benefit Services in the first quarter, so investors should watch whether biosimilar adoption and specialty volume keep offsetting pressure in large client relationships. The second watchpoint is whether Cigna Healthcare can preserve its pricing discipline without giving back the margin gains. The first-quarter medical care ratio of 79.8% was better than a year ago, but the company's full-year 2026 outlook still calls for a Cigna Healthcare medical care ratio of 83.7% to 84.7% (The Cigna Group Q1 2026 release). That implies some normalization ahead. Finally, investors should watch whether customer relationships stabilize after recent transitions. Pharmacy customers were 121.0 million at March 31, 2026, down from 123.6 million at year-end 2025, while total customer relationships fell to 185.5 million from 188.4 million (The Cigna Group Q1 2026 release). If specialty economics and commercial margins keep improving, CI can work even with modest churn. Key signals for investors. * Evernorth generated $58.4 billion of first-quarter 2026 adjusted revenue, far outweighing Cigna Healthcare's $11.5 billion, which reinforces that CI is a health-services platform as much as an insurer (The Cigna Group Q1 2026 release). * Specialty and Care Services pre-tax income rose 20% in the first quarter of 2026 even as Pharmacy Benefit Services income fell 28%, showing where the earnings mix is improving (The Cigna Group Q1 2026 release). * Cigna Healthcare's medical care ratio improved to 79.8% in Q1 2026 from 82.2% a year earlier, suggesting pricing and portfolio shaping are helping offset insurance-cost noise (The Cigna Group Q1 2026 release). * Cigna ended Q1 2026 with $7.0 billion in cash and a 42.3% debt-to-capitalization ratio, while 2025 buybacks totaled about $3.6 billion, supporting continued per-share earnings growth (Cigna Q1 2026 10-Q; The Cigna Group FY2025 release). Sources. * https://www.sec.gov/Archives/edgar/data/1739940/000114036126017971/ef20071317_ex99-1.htm * https://www.sec.gov/Archives/edgar/data/1739940/000173994026000043/ci-20260331.htm * https://www.sec.gov/Archives/edgar/data/1739940/000114036126003768/ef20064751_ex99-1.htm * https://www.sec.gov/Archives/edgar/data/1739940/000173994026000006/ci-20251231.htm * https://investors.thecignagroup.com/overview/default.aspx * https://data.sec.gov/submissions/CIK0001739940.json